J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial

Submitted by admin on May 21, 2024 - 11:17am

Source:

Clinical Trials Arena

News Tags:

Headline:

snippet:

The company’s monoclonal antibody met primary and secondary endpoints as a maintenance therapy for ulcerative colitis in a Phase III trial.

Search form